Title:
Case Studies and Patient Stories

dc.contributor.authorDevinder Kumar
dc.contributor.authorBrijesh Pawan Kumar
dc.contributor.authorRaj N. Kumar
dc.contributor.authorPratistha Singh
dc.date.accessioned2026-02-19T14:53:55Z
dc.date.issued2025
dc.description.abstractPharmacological metabolism issues put patient safety at risk by raising the possibility of side effects and inadequate treatment results. This summary attempts to explain the challenges associated with drug metabolism, particularly long-term polypharmacy with metabolites -when an unintended change has direct and clinically meaningful effects. This is done through a series of cases and patient stories. Metabolism typically consists of a series of enzymatic reactions that occur primarily in the liver and result in drugs being converted into water-soluble forms for excretion. Nevertheless, it is a factor that can be disrupted by genetic polymorphisms, liver diseases affecting its expression or function, drug interactions, and age-related changes in physiological mechanisms. Metabolites can lead to bioaccumulation of a drug, poor therapeutic effects, or adverse events if metabolism is incomplete. A patient with a CYP2D6 enzyme deficiency may convert codeine to morphine more slowly, resulting in inadequate pain relief. Another example is a distant psychiatric patient with underlying liver disease who experiences significant inadequacy of benzodiazepine metabolism, leading to prolonged sedation and respiratory depression. There is also an example of polypharmacy, in which a patient taking multiple medications, including a strong CYP3A4 inhibitor, receives a toxic amount of a normally safe dose because the metabolic clearance rate is reduced. They are important examples of incomplete drug metabolism and underscore the imperative incorporation of precise, personalized medicine techniques, including genetic testing, close monitoring of liver function tests (which would account for gender differences in response), and thorough consideration of possible interactions between pharmaceutical agents that contribute to individual variability. This, in turn, allows healthcare professionals to provide more personalized treatment, minimize the risk of side effects, and improve patient outcomes. © 2025, Bentham Books imprint.
dc.identifier.doi10.2174/9798898812492125010008
dc.identifier.isbn9798898812492; 9798898812508
dc.identifier.urihttps://doi.org/10.2174/9798898812492125010008
dc.identifier.urihttps://dl.bhu.ac.in/bhuir/handle/123456789/65127
dc.publisherBentham Science Publishers
dc.subjectDisease
dc.subjectDrug interactions
dc.subjectDrug metabolism
dc.subjectPersonalized medicine techniques
dc.subjectPharmacogenomics
dc.titleCase Studies and Patient Stories
dc.typePublication
dspace.entity.typeBook chapter

Files

Collections